drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
HER2-directed antibody-drug conjugate composed of trastuzumab linked to a topoisomerase I inhibitor (deruxtecan); binds HER2, inhibits HER2 signaling and mediates ADCC, then internalizes to release a topo-I payload that induces DNA damage with a potential bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab Deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-directed antibody-drug conjugate composed of trastuzumab linked to a topoisomerase I inhibitor (deruxtecan). Trastuzumab binds HER2 to inhibit signaling and mediate ADCC, then the complex is internalized and the payload is released to inhibit topoisomerase I, causing DNA damage and cell death, with potential bystander effect.
drug_name
Trastuzumab deruxtecan (T-DXd)
nct_id_drug_ref
NCT06245824